Oncology

Bevacizumab Study Shows Influence of Physician Relationships on Prescribing

January 4th 2020

By The Center for Biosimilars Staff

The findings indicate that interventions that leverage physician relationships may assist with increasing uptake of new, high-value cancer treatments in place of low-value therapies.

Using Biosimilar Filgrastim May Lead to Shorter Hospitalization, Lower Cost in PBSC Mobilization

January 3rd 2020

By Kelly Davio

Using the biosimilar resulted in a significantly lower drug acquisition cost, at $533.40 in the biosimilar group versus $1261.90 in the reference group.

Sonia T. Oskouei, PharmD: Biosimilars in 2020

January 1st 2020

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses what she will be watching closely in the biosimilars space in early 2020.

Lee Schwartzberg, MD, FACP: Biosimilars and Patient Attitudes

December 27th 2019

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses how patients are responding to using biosimilars.

Tesh Khullar: Biosimilar Education in Oncology

December 26th 2019

Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses biosimilar education for patients and providers.

What Role for Anti-TNFs in Addressing Immune Checkpoint Inhibitor AEs?

December 25th 2019

By Kelly Davio

Given that anti–tumor necrosis factor (anti-TNF) agents are able to suppress mucosal inflammation, some have posited that these drugs could play a role in mitigating immune-related enterocolitis.

WHO Prequalifies Samsung Bioepis' Biosimilar Trastuzumab

December 20th 2019

By Kelly Davio

The World Health Organization (WHO) this week prequalified its first biosimilar. The product, Samsung Bioepis’ biosimilar trastuzumab, Ontruzant, referencing Herceptin, could now become available to more patients with HER2-positive cancer in low- and middle-income countries.

New Long-term Safety and OS Data for Trazimera Show Similarity to Reference Trastuzumab

December 17th 2019

By Kelly Davio

Pfizer gained FDA approval for its biosimilar trastuzumab, Trazimera, in March 2019, and is slated to launch in the United States on February 15, 2020. Ahead of that milestone, researchers last week reported long-term safety and overall survival (OS) data for the Herceptin biosimilar in patients with HER2-positive metastatic breast cancer.

Sonia T. Oskouei, PharmD: Anticancer Biosimilars in 2019

December 16th 2019

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how anticancer biosimilars have played a role in oncology in 2019.

Canadian Study Shows Substantial Savings Possible With Use of Biosimilar Filgrastim

December 12th 2019

By Kelly Davio

During this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar filgrastim could result in substantial savings.